APA (7th ed.) Citation

T, P., A, S., Y, N., M, S., M, S., JM, J., . . . DR, C. (2024). The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC. JTO clinical and research reports, 5(2), 100637. https://doi.org/10.1016/j.jtocrr.2024.100637

Chicago Style (17th ed.) Citation

T, Patil, et al. "The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC." JTO Clinical and Research Reports 5, no. 2 (2024): 100637. https://doi.org/10.1016/j.jtocrr.2024.100637.

MLA (9th ed.) Citation

T, Patil, et al. "The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC." JTO Clinical and Research Reports, vol. 5, no. 2, 2024, p. 100637, https://doi.org/10.1016/j.jtocrr.2024.100637.